Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Initiator Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Initiator Pharma şirketinin toplam hissedar öz sermayesi DKK18.9M ve toplam borcu DKK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK20.2M ve DKK1.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

DKK 0

Borç

Faiz karşılama oranı	n/a
Nakit	DKK 14.49m
Eşitlik	DKK 18.92m
Toplam yükümlülükler	DKK 1.31m
Toplam varlıklar	DKK 20.23m

Son finansal sağlık güncellemeleri

Recent updates

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

May 31

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

Feb 27

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

May 20

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Jan 06

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Oct 26

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Jun 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: INIT 'nin kısa vadeli varlıkları ( DKK20.2M ) kısa vadeli yükümlülüklerini ( DKK1.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: INIT un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: INIT borçsuzdur.

Borcun Azaltılması: INIT un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: INIT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: INIT un, serbest nakit akışı her yıl % 18.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Initiator Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Recent updates

New minor risk - Shareholder dilution

Now 20% undervalued

New major risk - Financial position

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin